Effects of SGLT2 Inhibitors and GLP1 Receptor Agonists on Cardiovascular and Limb Events in Peripheral Artery Disease Patients

Explore the effects of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-i) and Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) on cardiovascular and limb events, with a primary focus on patients with Peripheral Artery Disease (PAD) in this comprehensive one-hour and seven-minute Cardiovascular Grand Rounds presentation. Delivered by Dr. Nedaa Skeik, MD, FACC, FACP, FSVM, from the Minneapolis Heart Institute Foundation, this lecture provides valuable insights into the latest research and clinical applications of these medications. Gain a deeper understanding of how SGLT2-i and GLP1-RA impact cardiovascular health and limb outcomes, particularly in the context of PAD management. Enhance your knowledge of cutting-edge treatments and their potential benefits for patients with complex cardiovascular conditions.

Effects of SGLT2-i & GLP1-RA on CV and Limb Events, Primarily in Patients with PAD | Nedaa Skeik, MD